These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18630351)

  • 21. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan.
    Ueda K; Hokugo J
    Expert Opin Drug Saf; 2020 Jul; 19(7):891-901. PubMed ID: 32342708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
    Muenzer J; Hendriksz CJ; Fan Z; Vijayaraghavan S; Perry V; Santra S; Solanki GA; Mascelli MA; Pan L; Wang N; Sciarappa K; Barbier AJ
    Genet Med; 2016 Jan; 18(1):73-81. PubMed ID: 25834948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
    Marín LL; Gutiérrez-Solana LG; Fernández AT
    Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: systematic review and meta-analysis].
    Alegra T; Eizerik DP; de Cerqueira CC; Pereira TV; Dornelles AD; Schwartz IV
    Cad Saude Publica; 2013 Nov; 29 Suppl 1():S45-58. PubMed ID: 25402250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy.
    Giugliani R; Hwu WL; Tylki-Szymanska A; Whiteman DA; Pano A
    Genet Med; 2014 Jun; 16(6):435-41. PubMed ID: 24202085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome.
    Galán-Gómez E; Guerrero-Rico A; Cáceres-Marzal C; Zambrano-Castaño M; Moreno-Tejero ML; Grande-Tejada AM; Fernández-Hernández S; Vaquerizo-Madrid J; Cardesa-García JJ
    Eur J Med Genet; 2008; 51(3):268-71. PubMed ID: 18396123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome).
    Serrano CD; Gomez JF
    J Investig Allergol Clin Immunol; 2011; 21(7):571-2. PubMed ID: 22312944
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
    Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
    PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hunter disease before and during enzyme replacement therapy.
    Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E
    Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
    Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B
    Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.
    Glamuzina E; Fettes E; Bainbridge K; Crook V; Finnegan N; Abulhoul L; Vellodi A
    J Inherit Metab Dis; 2011 Jun; 34(3):749-54. PubMed ID: 21327479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Giugliani R; Harmatz P; Martin R; Ramaswami U; Vellodi A; Wraith JE; Cleary M; Gucsavas-Calikoglu M; Puga AC; Shinawi M; Ulbrich B; Vijayaraghavan S; Wendt S; Conway AM; Rossi A; Whiteman DA; Kimura A
    Genet Med; 2011 Feb; 13(2):95-101. PubMed ID: 21150784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
    Kim S; Whitley CB; Jarnes Utz JR
    Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idursulfatase therapy in mucopolysaccharidosis type II: after 2.5 years of treatment--no benefit for older patients with multisystem involvement.
    Gucev ZS; Tasic V
    Pediatr Neurol; 2012 Mar; 46(3):199-200; author reply 200. PubMed ID: 22353301
    [No Abstract]   [Full Text] [Related]  

  • 40. [Idursulfase desensitization in a child with Hunter syndrome (mucopolysaccharidosis II)].
    Bustamante LL; Garavaglia L; Garramone EI; Amartino H; Parisi CA
    Arch Argent Pediatr; 2021 Feb; 119(1):e41-e44. PubMed ID: 33458989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.